Group 1 - The core point of the article is that Jinbo Biopharmaceutical (920982) has received approval from the China Securities Regulatory Commission (CSRC) for a specific stock issuance, which is valid for 12 months from the date of approval [1] - As of January 23, 2026, Jinbo Biopharmaceutical's stock closed at 229.45 yuan, up 1.08% from the previous trading day, with a total market capitalization of 26.402 billion yuan [1] - The stock opened at 230.0 yuan, reached a high of 233.98 yuan, and a low of 229.0 yuan, with a trading volume of 1.7 billion yuan and a turnover rate of 1.34% [1] Group 2 - The company will handle related matters based on the approval and authorization from the shareholders' meeting, ensuring timely information disclosure [1]
锦波生物（920982）披露向特定对象发行股票获证监会注册批复，1月23日股价上涨1.08%